Literature DB >> 2479715

Comparison of antigenic sites of subtype-specific respiratory syncytial virus attachment proteins.

E E Walsh1, C B Hall, J J Schlesinger, M W Brandriss, S Hildreth, P Paradiso.   

Abstract

A panel of 19 monoclonal antibodies (MAbs) were used to probe the antigenic relationships between the G (attachment) proteins of A and B respiratory syncytial virus (RSV) subtypes (GA and GB). At least three and two antigenic sites were present on GA and GB, respectively, including a shared neutralizing site. Most of the antibodies had some degree of complement-independent neutralizing capacity, but in common was a large neutralization-resistant fraction of virus (range 13 to 78%). Passive administration of MAbs to the cross-reactive antigenic site reduced pulmonary virus titres of both A and B subtype virus in the cotton rat model. Protection with subtype-specific MAbs, however, did not always correlate with in vitro neutralizing capacity. The cross-reactive antigenic site appears to be stable to denaturation by polyacrylamide gel electrophoresis and is present on the unglycosylated and partially glycosylated forms of GA and GB by Western blot analysis of infected cell lysates.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2479715     DOI: 10.1099/0022-1317-70-11-2953

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  24 in total

1.  Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.

Authors:  Margarita Magro; David Andreu; Paulino Gómez-Puertas; José A Melero; Concepción Palomo
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice.

Authors:  Yoshihiko Murata; Seana C Catherman
Journal:  Vaccine       Date:  2012-06-19       Impact factor: 3.641

Review 3.  Therapeutic targeting of respiratory syncytial virus G-protein.

Authors:  Lawrence M Kauvar; Jennifer L Harcourt; Lia M Haynes; Ralph A Tripp
Journal:  Immunotherapy       Date:  2010-09       Impact factor: 4.196

Review 4.  The good and evil of complement activation in HIV-1 infection.

Authors:  Qigui Yu; Richard Yu; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

Review 5.  Immunity to human and bovine respiratory syncytial virus.

Authors:  T G Kimman; F Westenbrink
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

6.  Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein.

Authors:  H Plotnicky-Gilquin; L Goetsch; T Huss; T Champion; A Beck; J F Haeuw; T N Nguyen; J Y Bonnefoy; N Corvaïa; U F Power
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

7.  Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells.

Authors:  Kai Yang; Jie Lan; Nicole Shepherd; Ningjie Hu; Yanyan Xing; Daniel Byrd; Tohti Amet; Corlin Jewell; Samir Gupta; Carole Kounga; Jimin Gao; Qigui Yu
Journal:  J Virol       Date:  2015-07-01       Impact factor: 5.103

Review 8.  Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

Authors:  José A Melero; Vicente Mas; Jason S McLellan
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

9.  Analysis of respiratory syncytial virus genetic variability with amplified cDNAs.

Authors:  W M Sullender; L Sun; L J Anderson
Journal:  J Clin Microbiol       Date:  1993-05       Impact factor: 5.948

10.  Bovine respiratory syncytial virus protects cotton rats against human respiratory syncytial virus infection.

Authors:  F M Piazza; S A Johnson; M E Darnell; D D Porter; V G Hemming; G A Prince
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.